Anyone reading the news this week knows what a stray remark from a CEO can do. But pharma executives don't have to mention "distressed babies"--or something equally telegenic--to get themselves in trouble. Regulators are keeping a closer eye on CEO statements, including media interviews and press releases, a top Pfizer ($PFE) attorney says. Report